The Mineralocorticoid Receptor Antagonist Tolerability Study–Diabetic Nephropathy (ARTS-DN), a pioneering multicenter, phase II clinical trial investigating the use of FIN in combination with a RAS inhibitor in individuals with DKD exhibited significant reductions in albuminuria and enhancements in the urine albumin-creatinine ratio (UACR) after 90 days of treatment with FIN (7.5–20 mg/day) in comparison to a placebo (91). This evidence concerns the gene NR3C2 and diabetic kidney disease.